SOURCE-LINKED STUDY SUMMARY
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Abstract summarizedQuality not appraised
- What was studied
- Randomized cardiovascular-safety trial comparing semaglutide with placebo, tracking cardiovascular death, nonfatal heart attack or stroke.
- Who / model studied
- 3297 people with type 2 diabetes, treated for 104 weeks. Most had cardiovascular disease, chronic kidney disease or both.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The primary outcome occurred in 6.6% versus 8.9%, meeting the trial's cardiovascular-safety criterion. Cardiovascular death rates were similar. Nonfatal strokes were fewer, but heart attacks showed no statistically clear difference. Kidney complications were fewer, while diabetic-eye complications were more frequent. Serious adverse events were fewer overall, but more participants stopped treatment, mainly for digestive symptoms.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa1607141